Poolbeg Pharma PLC - London-based pharmaceutical company - Wins patent grants from the US Patent & Trademark Office for its POLB 001 and POLB 002 molecules. The former is used to treat influenza, while the latter is an RNA-based immunotherapy for respiratory virus infections. "The company is continuing working with its patent advisors to broaden and expand the POLB 001 and POLB 002 patent families," Poolbeg says.
"Enhancing the IP protection of these assets across key markets such as the US increases the overall value of these products to potential partners, particularly as we move closer to the commencement of our POLB 001 LPS human challenge trial next month with data expected by year end and monetisation to commence thereafter," says Chief Executive Jeremy Skillington.
Current stock price: 7.54 pence, up 26% in London
12-month change: down 30%
By Heather Rydings; heatherrydings@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Poolbeg Pharma (POLB)